• 1
    Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006; 23: 45163.
  • 2
    Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn’s disease – evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 312.
  • 3
    Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal; surgery. Gut 2005; 54: 23741.
  • 4
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance of infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 5
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 87685.
  • 6
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 7
    Bratcher JM, Burton IK. Toxicity of infliximab in the course of treatment of Crohn’s disease. Expert Opin Drug Saf 2006; 5: 916.
  • 8
    Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 145566.
  • 9
    Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993; 94: 17481.
  • 10
    Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of the human anti-TNF-ALPHA monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 19849.
    Direct Link:
  • 11
    Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 759.
    Direct Link:
  • 12
    Kamm MA. Review article: biological drugs in Crohn’s disease. Aliment Pharmacol Ther 2006; 24: 809.
  • 13
    Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther 2004; 20: 133746.
  • 14
    Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005; 129: 80718.
  • 15
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. New Engl J Med. 2007; 357: 23950.
  • 16
    Danese S, Semeraro S, Armuzzi A, et al. Biological therapies for inflammatory bowel disease: research drives clinics. Mini Rev Med Chem 2005; 6: 77184.
  • 17
    Van den Brande JM, Braat H, Van Den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003; 124: 177485.
  • 18
    Winthrop KL. Risk and prevention of TB and other serious opportunistic infections associated with the inhibition of tumour necrosis factor. Nature Clin Pract Rheumatol 2006; 2: 60210.
  • 19
    Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Inf Dis 2004; 38: 12615.
  • 20
    MacKey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol 2007; 44: 2657.
  • 21
    Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 2007; 67: 170323.
  • 22
    Kunst H. Diagnosis of latent TB infection: the potential role of new technologies. Respir Med 2006; 100: 2098106.
  • 23
    World Health Organisation Rockville: Fact Sheet No 104: TB. (accessed 27/12/2006) 2006
  • 24
    Fauci AS, Touchette NA, Folkers GK. Emerging infectious diseases: a 10-year perspective from the national institute of allergy and infectious diseases. Emerg Infect Dis (serial on the internet) 2005: vol 11, no. 4. (accessed on 21/06/07)
  • 25
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab a tumor necrosis factor alpha neutralising agent. N Engl J Med 2001; 245: 1098104.
  • 26
    Hommes DW, Oldenburg B, Van Bodegraven, et al. Guidelines for treatment with infliximab for Crohn’s disease. Neth J Med 2006; 64: 21929.
  • 27
    Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthr Rheum 2004; 50: 3729.
  • 28
    Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 75790.
  • 29
    Gomez-Reino JJ, Carmona L, Rodriguez Valverde V, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in TB risk: a multicenter surveillance report. Arthr Rheum 2003; 48: 21227.
  • 30
    Askling J, Fored M, Brandt L, et al. Risk and case characteristic of TB in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthr Rheum 2005; 52: 198692.
  • 31
    Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 82934.
  • 32
    Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 1931.
  • 33
    Lichtenstein GR. Revisiting safety considerations of biologic therapy. 2007. (accessed 16 August)
  • 34
    Seiderer J, Goeke B, Ochsenkuehn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study of 100 patients of a German university hospital. Digestion 2004; 70: 39.
  • 35
    Mohan AK, Cote TR, Block JA, et al. TB following the use of etanercept a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 2959.
  • 36
    Winthrop KL, Siegel JN, Jereb J, et al. TB associated with therapy against tumor necrosis factor alpha. Arthr Rheum 2005; 52: 296874.
  • 37
    Center for Biologics Evaluation and Research. Safety Update on TNF-α Antagonists: Infliximab and Etanercept. FDA publication, 2007. (accessed 21/06/07)
  • 38
    Abbot Laboratories. Abbott Pharmaceuticals Prescribing Information for Adalimumab (Humira). 2007. (accessed 21/06/07)
  • 39
    FDA publication. Advisory Committee Briefing Document for HUMIRA March 2003; (accessed 21/06/07)
  • 40
    Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 88994.
  • 41
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, et al. Adalimumab for the maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM Trial. Gastroenterology 2007; 132: 5265.
  • 42
    Tam LS, Li EK, Wong SM, et al. Risk factors and clinical features for TB among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 2002; 31: 296300.
  • 43
    Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 10705.
  • 44
    Hernandez-Cruz B, Ponce-de-Leon RS, Sifuentes-Osornio J, et al. TB prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case–control study. Clin Exp Rheumatol 1999; 17: 817.
  • 45
    Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium TB infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16: 913.
  • 46
    Lipsky PE, Van Der Heijde DM, St Clair EW, Furst DE, Breedveld FC. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594602.
  • 47
    Westhovens R, Yocum D, Han J, Berman Astrusberg I. The safety of infliximab combined with background treatments among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthr Rheum 2006; 54: 107586.
  • 48
    Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41: S199203.
  • 49
    Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 169: 46207.
  • 50
    Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 73140.
  • 51
    Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent TB: possible role for limiting pathology. Infect Immun 2001; 69: 184755.
  • 52
    Bekker LG, Freeman S, Murray PJ, et al. TNF-alpha controls intracellular mycobacteria growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001; 166: 672834.
  • 53
    Hehlgans T, Pfeffer K. The intriguing biology of the tumor necrosis factor/tumor necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 120.
  • 54
    Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against mycobacterium TB in mice. Immunity 1995; 2: 56172.
  • 55
    Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacteral immunity. J Infect Dis 2006; 194: 48692.
  • 56
    Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-TB T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8: R114.
  • 57
    ATS/CDC Statement Committee on Latent TB Infection. Targeted Tuberculin Testing and Treatment of Latent TB Infection. CDC Morbidity and Mortality, 2007. (accessed 21/06/07)
  • 58
    Dasgupta K, Menzies D. Cost effectiveness of TB control strategies among immigrants and refugees. Eur Respir J 2005; 25: 110716.
  • 59
    Salmon-Ceron D. Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann Med Interne (Paris) 2002; 153: 42931.
  • 60
    Richeldi L. An update on the diagnosis of TB infection. Am J Respir Crit Care Med 2006; 174: 73642.
  • 61
    Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 30913.
  • 62
    Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis; study in a population with a high prevalence of TB. Ann Rheum Dis 2005; 64: 13601.
  • 63
    American Thoracic Society. Targeted Tuberculin Testing and Treatment of Latent TB Infection. ATS Guidelines, American Thoracic Society, 1999 (accessed 20/06/07)
  • 64
    British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing M TB infection and disease in patients due to start anti-TNF alpha treatment. Thorax 2005; 60: 8005.
  • 65
    Rampton DS. Preventing TB in patients with Crohn’s disease needing infliximab or other anti-TNF therapy. Gut 2005; 54: 13602.
  • 66
    Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing TB contacts. Am J Respir Crit Care Med 2007; 175: 61827.
  • 67
    Ferrara G, Losi M, D’Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with mycobacterium TB a prospective study. Lancet 2006; 267: 132834.
  • 68
    Diel R, Nienhaus A, Lange C, et al. TB contact investigation with a new specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006; 7: 77.
  • 69
    Chapman AL, Munkanata M, Wilkinson KA, et al. Rapid detection of active and latent TB infection in HIV-positive individuals by enumeration of mycobacterium TB-specific T cells. AIDS 2002; 16: 228593.
  • 70
    Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of TB in South African children with a T-cell based assay: a prospective cohort study. Lancet 2004; 364: 2196203.
  • 71
    Piana F, Codescasa LR, Cavallerio P, et al. Use of a T-cell based test for detection of TB infection among immunocompromised patients. Eur Respir J 2006; 28: 314.
  • 72
    Madhukar P, Lewinsohn DM. Interferon-gamma assays for TB: is anergy the achilles’ heel? Am J Respir Crit Care Med 2005; 172: 51921.
  • 73
    Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of TB infection. Am J Respir Crit Care Med 2005; 172: 6315.
  • 74
    Efthimiou P, Sood S. Quantiferon TB gold test: the new standard for screening of latent TB in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 276.
  • 75
    Ravn P, Munk ME, Andersen AB, et al. Reactivation of TB during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scand J Infect Dis 2004; 36: 499501.
  • 76
    NICE CG33 Tuberculosis: Full Guideline. Cost Effectiveness of Testing Strategies. London, Royal College of Physicians, 2007 (accessed 15/09/2007)
  • 77
    Stas P, D’Hoore A, Van Assche G, et al. Miliary TB following infliximab therapy for Crohn’s disease: a case report and review of the literature. Acta Gastroenterol Belg 2005; 69: 21720.
  • 78
    Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent TB infection in patients treated with tumor necrosis factor antagonists. Arth Rheum 2005; 52: 176672.
  • 79
    Perez JL, Kupper H, Spencer-Green GT. Impact of Screening for Latent TB Prior to initiation of Anti-TNF Therapy in North America and Europe. Ann Rheum Dis. 2006; 64(Suppl. III) 86. (Abstract accessed on-line via:
  • 80
    Sichletidis L, Settas L, Spyratos D, et al. TB in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 112732.
  • 81
    Vlachaki E, Psathakis K, Tsintiris K, et al. Delayed response to anti-TB treatment in a patient on infliximab. Respir Med 2005; 99: 64852.
  • 82
    Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent TB infection. Can Med Assoc J 2003; 168: 11536.
  • 83
    American Thoracic Society. Targeted tuberculin testing and treatment of latent TB infection. Am J Respir Crit Care Med 2000; 161: S22147.
  • 84
    Keane J. TNF-blocking agents and TB: new drugs illuminate and old topic. Rheumatology 2005; 44: 71420.
  • 85
    Page KR, Sifakis R, Montes de Oca R, et al. Improved adherence and less toxicity with rifampicin vs isoniazid for treatment for latent TB: a retrospective study. Arch Intern Med 2006; 166: 186370.
  • 86
    Hamilton C. TB in the cytokine era: what rheumatologists need to know. Arth Rheum 2003; 48: 208591.